Brought to you by 
Dermelix gains EspeRare's DMX101 for ultra-rare disease XLHED
05 Apr 2019
Executive Summary
Dermelix Biotherapeutics and the Swiss non-profit organization EspeRare Foundation are collaborating on the development and commercialization of DMX101 (formerly known as ED1200 and ER004) for the ultra-rare pediatric disease X-linked hypohidrotic ectodermal dysplasia (XLHED), which is caused by a deficiency of ectodysplasin A (EDA), a protein required for the normal formation of structures such as sweat and respiratory glands, skin, hair, and teeth.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dermelix gains EspeRare's DMX101 for ultra-rare disease XLHED
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice